Previous 10 | Next 10 |
It's been a downright miserable year for Amarin (NASDAQ: AMRN) so far. The stock imploded earlier this year after a judge invalidated key patents for hypertriglyceridemia drug Vascepa. And Amarin's shares are still down nearly 70% year to date. Investors hoped for at least a little b...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2020 Q2 earnings Read more ...
Amarin ( AMRN ) Q2 results : More news on: Amarin Corporation plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades Veteran Cardiovascular Commercial Executive Hired to Lead Focused Launch DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -...
Amarin (NASDAQ: AMRN ) : Q2 Non-GAAP EPS of $0.04 beats by $0.11 ; GAAP EPS of $0.01 beats by $0.09 . More news on: Amarin Corporation plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Total Revenue Increased 34% in Second Quarter 2020 Compared to Second Quarter 2019 Despite COVID-19 Headwinds Multiple Upcoming Milestones Regarding VASCEPA ® Opportunity in United States and Internationally Management to Host Conference Call Today at 7:30 a.m. ET ...
Amarin (NASDAQ: AMRN ) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. The consensus EPS Estimate is -$0.07 vs. $0.02 in 2Q19 and the consensus Revenue Estimate is $149.48M (+48.3% Y/Y). Over the last 2 years, AMRN has beaten EPS esti...
What luck has gave you will probably leave you ."― Amit Kalantri I have had a couple of requests to revisit this name. A full investment analysis is as follows. The stock also continues to look like a good covered call candidate at current trading levels. The stock has formed a sol...
New data from the REDUCE-IT clinical trial (REVASC analysis) presented at the American Society for Preventive Cardiology Virtual Summit on CVD Prevention showed that the administration of 4 g/day of Amarin's (NASDAQ: AMRN ) Vascepa (icosapent ethyl) resulted in a 34% reduction in first ...
VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study First and total coronary revascularization event reductions of 34% and 36%, respectively, shown...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...